Hearts & Minds Investments

Results Announcement

Hearts and Minds Investments Limited increases fully franked dividend to 9.5cps

+10.8% PER ANNUM
Investment performance since inception (Nov 2018)

9.5cps
Increased interim fully franked dividend

6.1%
Projected annualised net dividend yield#

7.9%
Total shareholder return 6 months to 31 December 25

The Hearts and Minds Investments Limited (ASX:HM1) Board of Directors has declared an increased interim fully franked dividend of 9.5 cents per share payable in April 2026. For the half-year ended 31 December 2025, Hearts and Minds Investments Limited reported a total comprehensive income after tax of $3.0 million (half-year 2024: $115.3 million). The Board remains confident in the Company's ability to maintain its dividend policy, and its stated intention of increasing fully franked dividends by 0.5cps every 6 months for the foreseeable future. This intention is supported by the franking balance and tax liabilities on the balance sheet, which together (if and when the tax liabilities are paid) support a total of 83cps of fully franked dividends. The Company holds a profits reserve equal to 86cps.

As a listed investment company, Hearts and Minds Investments Limited's returns are driven by the change in value of its investment portfolio. For the half-year ended 31 December 2025, the value of the portfolio was largely flat, with investment performance after expenses and before all taxes of 0.4% (half-year 2024: 23.6%). While the portfolio saw some strong gains in Cameco and Taiwan Semiconductor Manufacturing Company, these returns were tempered by negative movements in Block, Guzman y Gomez and Zillow over the 6-month period. The half-year performance also reflects the impact of writing down the value of Corporate Travel Management (ASX:CTD) to zero following its suspension from trading and negative market update.

This period of flat performance of the investment portfolio has marginally reduced our investment returns since inception to 10.8% per annum.

Performance to 31 December 2025	6 Months	1 Year	3 Years per annum	Since Inception[1] per annum
HM1 investment portfolio performance	0.4%	2.0%	14.7%	10.8%
MSCI World Accumulation Index (AUD)	9.2%	12.7%	22.6%	15.2%

HM1 Investment Performance is calculated after expenses and before all taxes. The comparator is the MSCI World Accumulation Index in AUD, gross of withholding tax.
[1]Inception was 14 November 2018.

Despite the flat portfolio performance, Hearts and Minds Investments Limited delivered a Total Shareholder Return (TSR) of 7.9% for the six months to 31 December 2025. This was driven by a 4.9% increase in share price (from $3.04 on 30 June 2025 to $3.19 on 31 December 2025) and the payment of a fully franked final dividend of 9.0 cents per share in October 2025. Since inception, Hearts and Minds Investments Limited has paid fully franked dividends amounting to a total of 77.5 cents per share to shareholders prior to the announcement of this interim dividend of 9.5 cents per share.

$90.5m
Donations since 2016

In line with its philanthropic objective, Hearts and Minds Investments Limited provides financial support to leading Australian medical research organisations to fund the development of new medicines and treatments and drive a new generation of medical research in Australia. Hearts and Minds Investments Limited and its participating fund managers forego any fees and instead an amount equivalent to 1.5% of net tangible assets per annum is donated to designated medical research organisations. In the half-year to 31 December 2025, Hearts and Minds Investments Limited paid $5.4 million in funding to medical research and has increased its accrual for future donations by $0.6m from $8.2m to $8.8m.

#Projected annualised fully franked dividend over the next 12 months of 19.5cps divided by share price on 31 December 2025. All figures as of 31 December 2025 unless otherwise stated. This announcement has been authorised by the Board of Hearts and Minds Investments Limited.

Hearts and Minds Investments Limited offers a compelling investment through a concentrated portfolio of global equities recommended by a select panel of successful fund managers. The investment returns of the portfolio are underpinned by a fully franked dividend that is paid half-yearly to shareholders. All investment fees are waived and instead an equivalent amount is contributed to fund medical research in Australia. This represents a professionally managed investment and a meaningful social return.

The Board of Directors would also like to thank you, our shareholders, for supporting the advancement of medical research in Australia through your investment in Hearts and Minds Investments Limited.

For further information on Hearts and Minds Investments Limited and view the Half-Year Report to 31 December 2025, please visit hm1.com.au.

9.5cps

Latest dividend payable 16 April 2026

83cps^

Fully franked dividends supported by profit reserve

Fully franked dividends since inception



*The Board of HM1 has resolved to increase dividends by 0.5cps every 6 months for the foreseeable future subject to there being no sustained period of investment market underperformance **Prior to FY24, HM1 paid dividends annually. The dividend in April 2023 was 13.5cps. For the purposes of this chart, we have allocated 7.0cps to the FY23 financial year. Dividends prior to FY23 were 12.0cps in April 2021 and 13.5cps in April 2022.

Interim fully franked dividend dates

Ex-dividend date:	25 February 2026
Record date:	26 February 2026
DRP election date:	11 March 2026
Payment date:	16 April 2026

^Based on franking balance of 11cps (supporting franked dividends of 26cps), plus tax liabilities on balance sheet of 25cps which, if and when paid as tax, will support franking of a further 57cps of dividends. The Company holds a profits reserve equal to 86cps.

About Hearts & Minds

Hearts and Minds Investments Limited (ASX: HM1) gives investors access to a concentrated global equities portfolio built from high conviction ideas from selected leading fund managers. Instead of management fees, 1.5% of NTA is donated annually to Australian medical research. Over $90.5m has been donated to pioneering medical research since 2016, together with the Sohn Hearts & Minds Conference.

ACCESS BRIGHT MINDS

Gain access to selected leading global fund managers who share their high conviction ideas pro bono.

PERFORMANCE & GROWTH

Delivering shareholder returns from a concentrated portfolio of global equities, underpinned by fully franked dividends.

PURPOSE & IMPACT

A unique model that donates 1.5% of NTA annually to pioneering Australian medical research in lieu of usual management fees.

All figures as at 31 December 2025 unless otherwise stated. This is general information only and does not consider your objectives, financial situation, or needs. You should read the relevant offer documents and seek independent financial advice before making any investment decisions. All investments carry risk, including the potential loss of capital. Past performance is not a reliable indicator of future returns. Hearts and Minds Investments Limited is a Corporate Authorised Representative (CAR No. 1317870) of Quay Arktos RE Services Limited (AFSL No. 563036). This announcement has been authorised by the Board of Hearts and Minds Investments Limited.